{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:51:29Z","timestamp":1792651889904,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006710","name":"Wayne State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007284","name":"School of Medicine, Wayne State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009528","name":"Children\u2019s Hospital of Michigan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017302","name":"Barbara Ann Karmanos Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004032","name":"Jilin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA022453"],"award-info":[{"award-number":["P30 CA022453"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.bcp.2023.115759","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T17:04:11Z","timestamp":1692464651000},"page":"115759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms"],"prefix":"10.1016","volume":"216","author":[{"given":"Jenna L.","family":"Carter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"H\u00fcttemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2023.115759_b0005","unstructured":"SEER Cancer Stat Facts: Acute Myeloid Leukemia Bethesda, MD: National Cancer Institute; [Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html]."},{"issue":"5","key":"10.1016\/j.bcp.2023.115759_b0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-020-0323-4","article-title":"Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century","volume":"10","author":"Pulte","year":"2020","journal-title":"Blood Cancer J."},{"issue":"51\u201352","key":"10.1016\/j.bcp.2023.115759_b0015","first-page":"863","article-title":"The treatment of elderly patients with acute myeloid leukemia","volume":"108","author":"Krug","year":"2011","journal-title":"Deutsches Arzteblatt Int."},{"issue":"1","key":"10.1016\/j.bcp.2023.115759_b0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group","volume":"27","author":"B\u00fcchner","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2023.115759_b0025","first-page":"125","article-title":"Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia","volume":"4","author":"Saliba","year":"2021","journal-title":"Cancer drug resistance (Alhambra, Calif)."},{"key":"10.1016\/j.bcp.2023.115759_b0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bcp.2019.01.015","article-title":"A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics","volume":"162","author":"Knight","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2023.115759_b0035","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.bcp.2023.115759_b0040","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.bcp.2023.115759_b0045","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2023.115759_b0050","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2023.115759_b0055","doi-asserted-by":"crossref","unstructured":"Richard-Carpentier G, DiNardo CD. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Therapeutic advances in hematology. 2019;10:2040620719882822.","DOI":"10.1177\/2040620719882822"},{"issue":"11","key":"10.1016\/j.bcp.2023.115759_b0060","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1007\/s00432-022-03930-5","article-title":"Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia","volume":"148","author":"Fleischmann","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcp.2023.115759_b0065","doi-asserted-by":"crossref","first-page":"106317","DOI":"10.1016\/j.leukres.2020.106317","article-title":"Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study","volume":"91","author":"Lou","year":"2020","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.bcp.2023.115759_b0070","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00277-020-04321-x","article-title":"Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"100","author":"Schuler","year":"2021","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115759_b0075","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.bcp.2023.115759_b0080","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2023.115759_b0085","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.bcp.2023.115759_b0090","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nature Cancer."},{"key":"10.1016\/j.bcp.2023.115759_b0095","first-page":"13","article-title":"Detection of mycoplasma contaminations","volume":"290","author":"Uphoff","year":"2005","journal-title":"Methods Mol. Biol."},{"issue":"7","key":"10.1016\/j.bcp.2023.115759_b0100","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2014.72","article-title":"Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199","volume":"28","author":"Niu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2023.115759_b0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bcp.2017.11.022","article-title":"Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo","volume":"148","author":"Su","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115759_b0110","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"17","key":"10.1016\/j.bcp.2023.115759_b0115","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2005.07.450","article-title":"Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies","volume":"23","author":"Rudek","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.bcp.2023.115759_b0120","doi-asserted-by":"crossref","first-page":"34785","DOI":"10.18632\/oncotarget.9185","article-title":"Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.bcp.2023.115759_b0125","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1158\/1078-0432.CCR-10-1707","article-title":"Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia","volume":"16","author":"Xie","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.bcp.2023.115759_b0130","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2008-09-179812","article-title":"RUNX1 regulates phosphoinositide 3-kinase\/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia","volume":"114","author":"Edwards","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2023.115759_b0135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcph.1275","article-title":"Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients","volume":"59","author":"Bao","year":"2019","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115759_b0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00502-7","article-title":"The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML","volume":"11","author":"Qiao","year":"2021","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.bcp.2023.115759_b0145","doi-asserted-by":"crossref","first-page":"e79106","DOI":"10.1371\/journal.pone.0079106","article-title":"Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51","volume":"8","author":"Xie","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.bcp.2023.115759_b0150","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bcp.2023.115759_b0155","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2023.115759_b0160","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1158\/0008-5472.CAN-09-0458","article-title":"Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines","volume":"69","author":"Schaefer","year":"2009","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.bcp.2023.115759_b0165","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1345\/aph.1E612","article-title":"5-azacytidine and decitabine monotherapies of myelodysplastic disorders","volume":"39","author":"Kuykendall","year":"2005","journal-title":"Ann. Pharmacother."},{"issue":"15","key":"10.1016\/j.bcp.2023.115759_b0170","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/0006-2952(76)90407-X","article-title":"Inhibition of protein synthesis in 5-azacytidine-treated HeLa cells","volume":"25","author":"Lee","year":"1976","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2023.115759_b0175","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discovery"},{"issue":"1","key":"10.1016\/j.bcp.2023.115759_b0180","article-title":"Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells","volume":"2","author":"Luedtke","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2023.115759_b0185","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2023.115759_b0190","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","author":"Tahir","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2023.115759_b0195","article-title":"Targeting MCL-1\/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"issue":"491","key":"10.1016\/j.bcp.2023.115759_b0200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.bcp.2023.115759_b0205","first-page":"2509","article-title":"Mutation of IDH1 aggravates the fatty acid-induced oxidative stress in HCT116 cells by affecting the mitochondrial respiratory chain","volume":"19","author":"Li","year":"2019","journal-title":"Mol. Med. Rep."},{"issue":"10","key":"10.1016\/j.bcp.2023.115759_b0210","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrc3365","article-title":"Mitochondria and cancer","volume":"12","author":"Wallace","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2023.115759_b0215","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4155\/fmc-2017-0011","article-title":"Targeting cancer cell mitochondria as a therapeutic approach: recent updates","volume":"9","author":"Cui","year":"2017","journal-title":"Future Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2023.115759_b0220","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.celrep.2016.05.052","article-title":"Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics","volume":"15","author":"Navarro","year":"2016","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.bcp.2023.115759_b0225","first-page":"227","article-title":"Cancer metabolism: fatty acid oxidation in the limelight. Nature reviews","volume":"13","author":"Carracedo","year":"2013","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2023.115759_b0230","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood-2014-02-554204","article-title":"A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"issue":"3191","key":"10.1016\/j.bcp.2023.115759_b0235","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.bcp.2023.115759_b0240","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3389\/fonc.2018.00500","article-title":"The Influence of Metabolism on Drug Response in Cancer","volume":"8","author":"Zaal","year":"2018","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115759_b0245","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.7314\/APJCP.2014.15.4.1823","article-title":"HIF-1\u03b1 and GLUT1 gene expression is associated with chemoresistance of acute myeloid leukemia","volume":"15","author":"Song","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.bcp.2023.115759_b0250","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3892\/ol.2016.4600","article-title":"Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia","volume":"12","author":"Song","year":"2016","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.bcp.2023.115759_b0255","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.bcp.2023.115759_b0260","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3390\/cancers12092400","article-title":"Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation","volume":"12","author":"Liu","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.bcp.2023.115759_b0265","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1111\/jcmm.13886","article-title":"Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1","volume":"22","author":"Luedtke","year":"2018","journal-title":"J. Cell Mol. Med."},{"issue":"17","key":"10.1016\/j.bcp.2023.115759_b0270","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2023.115759_b0275","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/leu.2017.243","article-title":"Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1","volume":"32","author":"Teh","year":"2018","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.bcp.2023.115759_b0280","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2018-99-113491","article-title":"Mcl-1\/CDK9 Targeting By AZD5991\/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions","volume":"132","author":"Carter","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2023.115759_b0285","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3324\/haematol.2020.260331","article-title":"Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition","volume":"107","author":"Carter","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bcp.2023.115759_b0290","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cmet.2017.09.009","article-title":"MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation","volume":"26","author":"Lee","year":"2017","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.bcp.2023.115759_b0295","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/ncb2488","article-title":"Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration","volume":"14","author":"Perciavalle","year":"2012","journal-title":"Nat. Cell Biol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115759_b0300","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.molcel.2018.02.005","article-title":"Dynamic Regulation of Long-Chain Fatty Acid Oxidation by a Noncanonical Interaction between the MCL-1 BH3 Helix and VLCAD","volume":"69","author":"Escudero","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2023.115759_b0305","doi-asserted-by":"crossref","first-page":"114253","DOI":"10.1016\/j.bcp.2020.114253","article-title":"Targeting mitochondrial respiration for the treatment of acute myeloid leukemia","volume":"182","author":"Carter","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115759_b0310","article-title":"Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy","volume":"5","author":"Carter","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2023.115759_b0315","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/cr.2017.155","article-title":"Mitochondrial metabolism and cancer","volume":"28","author":"Porporato","year":"2018","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.bcp.2023.115759_b0320","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nchembio.1712","article-title":"Targeting mitochondria metabolism for cancer therapy","volume":"11","author":"Weinberg","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"7","key":"10.1016\/j.bcp.2023.115759_b0325","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat. Med."},{"issue":"516","key":"10.1016\/j.bcp.2023.115759_b0330","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2863","article-title":"Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response","volume":"11","author":"Sharon","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.bcp.2023.115759_b0335","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discovery"},{"issue":"4","key":"10.1016\/j.bcp.2023.115759_b0340","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13040467","article-title":"Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2","volume":"13","author":"Culp-Hill","year":"2023","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.bcp.2023.115759_b0345","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1172\/JCI38942","article-title":"Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction","volume":"120","author":"Samudio","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bcp.2023.115759_b0350","doi-asserted-by":"crossref","first-page":"e2003782","DOI":"10.1371\/journal.pbio.2003782","article-title":"Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of \u03b2-oxidation","volume":"16","author":"Yao","year":"2018","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bcp.2023.115759_b0355","doi-asserted-by":"crossref","unstructured":"Farge T, Nakhle J, Lagarde D, Cognet G, Polley N, Castellano R, et al. CD36 drives metastasis and relapse in acute myeloid leukemia. Cancer Res. 2023.","DOI":"10.1158\/0008-5472.c.6816237.v1"},{"issue":"7","key":"10.1016\/j.bcp.2023.115759_b0360","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer discovery"},{"issue":"1","key":"10.1016\/j.bcp.2023.115759_b0365","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","article-title":"Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche.","volume":"19","author":"Ye","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"7635","key":"10.1016\/j.bcp.2023.115759_b0370","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nature20791","article-title":"Targeting metastasis-initiating cells through the fatty acid receptor CD36.","volume":"541","author":"Pascual","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2023.115759_b0375","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia","volume":"141","author":"Moujalled","year":"2022","journal-title":"Blood"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223003507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223003507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:20:14Z","timestamp":1762096814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223003507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":75,"alternative-id":["S0006295223003507"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115759","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115759"}}